REDWOOD CITY, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) — Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules for the treatment of genetically defined cancers and metabolic diseases, has confirmed that Thomas Butler, Biomea Fusion’s Chief Executive Officer, and Chairman of the Board, will be presenting at the upcoming 42nd Annual J.P. Morgan Healthcare Conference. The presentation is scheduled for Tuesday, January 9, 2024, from 8:15 am – 8:55 am PST. Additionally, Biomea management is set to conduct 1×1 meetings during the conference from January 8 to 11.
About Biomea Fusion
Biomea Fusion is a clinical-stage biopharmaceutical company that specializes in the discovery and development of covalent small molecules to address the needs of patients with genetically defined cancers and metabolic diseases. Covalent small molecules, synthetic compounds forming a permanent bond with their target proteins, offer several advantages over traditional non-covalent drugs. These advantages include enhanced target selectivity, reduced drug exposure, and the potential for a more profound and enduring treatment response.
Leveraging its proprietary FUSION™ System, Biomea Fusion is actively engaged in the discovery, design, and development of a pipeline featuring next-generation covalent-binding small molecule medicines. The company’s goal is to provide maximum clinical benefit to patients dealing with various cancers and metabolic diseases, including diabetes, with an ultimate aim to contribute to curative solutions.
Investors and stakeholders can anticipate valuable insights into Biomea Fusion’s groundbreaking work and future endeavors during the J.P. Morgan Healthcare Conference presentation. The company remains dedicated to advancing innovative therapies to improve the lives of patients facing challenging medical conditions.
